Amivantamab, lazertinib, and bevacizumab: a chemotherapy-free option for patients with advanced EGFR-mutant NSCLC with acquired resistance to a third-generation EGFR TKI

The Lancet Respiratory Medicine · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles